Allogeneic donor availability for hematopoietic stem cell transplantation in children with sickle cell disease

Pediatric Blood and Cancer

Volumn 62, Issue 7, 2015, Pages 1285-1287

  Justus, David ^a   Perez Albuerne, Evelio ^b   Dioguardi, Jacqueline ^b   Jacobsohn, David ^b   Abraham, Allistair ^b  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

BMT; Sickle cell disease; Transplantation

Indexed keywords

ADOLESCENT; ADULT; AGE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHILD; DONOR SELECTION; ETHNICITY; FEMALE; HLA MATCHING; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SICKLE CELL ANEMIA; UNRELATED DONORS; ALLOTRANSPLANTATION; ANEMIA, SICKLE CELL; COMPUTER SIMULATION; DONOR; FETUS BLOOD; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TEST; INFANT; MONTE CARLO METHOD; NEWBORN; PRESCHOOL CHILD; PROGNOSIS; SUPPLY AND DISTRIBUTION; YOUNG ADULT;

ADOLESCENT; ADULT; ANEMIA, SICKLE CELL; CHILD; CHILD, PRESCHOOL; COMPUTER SIMULATION; FEMALE; FETAL BLOOD; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; INFANT; INFANT, NEWBORN; MALE; MONTE CARLO METHOD; PROGNOSIS; RETROSPECTIVE STUDIES; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84929303346     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25439     Document Type: Article

References (20)

1. McGann PT. Sickle cell anemia: An underappreciated and unaddressed contributor to global childhood mortality. J Pediatr 2014; 65:18-22.
2. Walters MC, Storb R, Patience M, Leisenring W, Taylor T, Sanders JE, Buchanan GE, Rogers ZR, Dinndorf P, Davies SC, Roberts IA, Dickerhoff R, Yeager AM, Hsu L, Kurtzberg J, Ohene-Frempong K, Bunin N, Bernaudin F, Wong WY, Scott JP, Margolis D, Vichinsky E, Wall DA, Wayne AS, Pegelow C, Redding-Lallinger R, Wiley J, Klemperer M, Mentzer WC, Smith FO, Sullivan KM. Impact of bone marrow transplantation for symptomatic sickle cell disease: An interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease. Blood 2000; 95:1918-1924.
3. Locatelli F, Kabbara N, Ruggeri A, Ghavamzadeh A, Roberts I, Li CK, Bernaudin F, Vermylen C, Dalle JH, Stein J, Wynn R, Cordonnier C, Pinto F, Angelucci E, Socié G, Gluckman E, Walters MC, Rocha V. Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling. Blood 2013; 122:1072-1078.
4. Bernaudin F, Socie G, Kuentz M, Chevret S, Duval M, Bertrand Y, Vannier JP, Yakouben K, Thuret I, Bordigoni P, Fischer A, Lutz P, Stephan JL, Dhedin N, Plouvier E, Margueritte G, Bories D, Verlhac S, Esperou H, Coic L, Vernant JP, Gluckman E. Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood 2007; 110:2749-2756.
5. Panepinto J, Walters M, Carreras J, Marsh J, Bredeson CN, Gale RP, Hale GA, Horan J, Hows JM, Klein JP, Pasquini R, Roberts I, Sullivan K, Eapen M, Ferster A. Matched-related donor transplantation for sickle cell disease: Report from the Center for International Blood and Transplant Research. Br J Haematol 2007; 137:479-485.
6. Walters MC, Patience M, Leisenring W, Eckman JR, Buchanan GR, Rogers ZR, Olivieri NE, Vichinsky E, Davies SC, Mentzer WC, Powars D, Scott JP, Bernaudin F, Ohene-Frempong K, Darbyshire PJ, Wayne A, Roberts IA, Dinndorf P, Brandalise S, Sanders JE, Matthews DC, Appelbaum FR, Storb R, Sullivan KM. Barriers to bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant 1996; 2:100-104.
7. Krishnamurti L, Abel S, Maiers M, Flesch S. Availability of unrelated donors for hematopoietic stem cell transplantation for hemoglobinopathies. Bone Marrow Transplant 2003; 31:547-550.
8. Gragert L, Eapen M, Williams E, Freeman J, Spellman S, Baitty R, Hartzman R, Rizzo JD, Horowitz M, Confer D, Maiers M. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N Engl J Med 2014; 371:339-348.
9. Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, Eapen M, Fernandez-Vina M, Flomenberg N, Horowitz M, Hurley CK, Noreen H, Oudshoorn M, Petersdorf E, Setterholm M, Spellman S, Weisdorf D, Williams TM, Anasetti C. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007; 110:4576-4583.
10. Flomenberg N, Baxter-Lowe LA, Confer D, Fernandez-Vina M, Filipovich A, Horowitz M, Hurley C, Kollman C, Anasetti C, Noreen H, Begovich A, Hildebrand W, Petersdorf E, Schmeckpeper B, Setterholm M, Trachtenberg E, Williams T, Yunis E, Weisdorf D. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 2004; 104:1923-1930.
11. Ruggeri A, Eapen M, Scaravadou A, Cairo MS, Bhatia M, Kurtzberg J, Wingard JR, Fasth A, Lo Nigro, Ayas L, Purtill M, Boudjedir D, Chaves K, Walters W, Wagner MC, Gluckman J, Rocha E. Umbilical cord blood transplantation for children with thalassemia and sickle. Biol Blood Marrow Transplant 2011; 17:1375-1382.
12. Kollman C, Howe CW, Anasetti C, Antin JH, Davies SM, Filipovich AH, Hegland J, Kamani N, Kernan NA, King R, Ratanatharathorn V, Weisdorf D, Confer DL. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: The effect of donor age. Blood 2001; 98:2043-2051.
13. National Marrow Donor Program. Be The Match Focuses on Building a Younger Registry. https://bethematchclinical.org/research-and-news/browse-news/be-the-match-focuses-on-building-a-younger-registry. Published October 2012, Accessed October 4, 2014.
14. Avery S, Shi W, Lubin M, Gonzales AM, Heller G, Castro-Malaspina H, Giralt S, Kernan NA, Scaradavou A, Barker JN. Influence of infused cell dose and HLA match on engraftment after double-unit cord blood allografts. Blood 2011; 117:3277-3285. quiz 3478.
15. ClinicalTrials.gov. Pilot Study Evaluating Safety & Efficacy of a DCBT: NiCord® & UNM CBU to SCD Patients After Myeloablative Therapy. http://clinicaltrials.gov/ct2/show/NCT01590628?term = NCT01590628&rank = 1 Published April 15, 2012, Accessed June 19, 2014.
16. Rana S, Houston PE, Wang WC, Iyer RV, Goldsmith J, Casella JF, Reed CK, Rogers ZR, Waclawiw MA, Thompson B. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics 2014; 134:465-472.
17. Centers for Disease Control and Prevention NCfHSUS. Growth Charts - Z-score Data Files. http://www.cdc.gov/growthcharts/zscore.htm Published August 4, 2009, Accessed May 21, 2014.
18. Roberts C, Casella G. Monte Carlo Statistical Methods. New York: Springer 2004.
19. R Core Team. R: A Language and Environment for Statistical Computing URL http://www.R-project.org 2014.
20. Clinicaltrials.gov. Unrelated Donor Hematopoietic Cell Transplantation for Children with Severe Sickle Cell Disease Using a Reduced Intensity Conditioning Regimen / The SCURT Study. https://web.emmes.com/study/bmt2/protocol/0601_protocol/0601_protocol.html Published August 29, 2008, Accessed on June 19, 2014.